Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Yardbarker on MSN38m
Collin Morikawa and Rio Takeda Rewrite the Script of DominanceGolf, often a game of patience and calculated risks, has a way of humbling even the greatest players. Just when it seems like ...
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
Rio Takeda shot a blistering 8-under 64 to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia.
Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...
Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...
Rio Takeda hinted at what she was capable of last fall. She proved it Sunday in China. The 21-year-old rookie from Japan ...
Rio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s ...
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
LPGA Tour rookie Rio Takeda carded an 8-under-par 64 on Sunday to cruise to a six-stroke victory at the Blue Bay LPGA on ...
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
SANYA, China — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA’s Blue Bay tournament by six shots ahead of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback